The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study
Abstract
Background: Guidelines recommend selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) as first-line treatments for major depressive disorder (MDD) and emphasize the importance of early pharmacological treatment as key factors to treatment success. Objectives: To compare the MDD-related healthcare resource utilization (HCRU) and cost among patients (1) with early vs late pharmacological treatment initiation and (2) achieving minimum therapeutic dose (MTD) early vs late. Methods: The MarketScan database (2010-2015) was used. Adults who were newly-treated with SSRI/SNRI within 12 months after the initial MDD diagnosis (index) were included. Patients who initiated SSRI/SNRI within 2 weeks of the index date were defined as early initiators; those who reached MTD within 4 weeks of index date were defined as early MTD achievers. MDD-related HCRU and costs per year after the index date were compared between early and late initiators and between early and late achievers using propensity score matching and generalized linear models. Results: Of the 55,539 patients, 60% were early initiators and 61% were early MTD achievers. The mean number of MDD-related outpatient visits per year were significantly higher for late initiator (6.7 vs 4.2, p p Conclusions: There is an opportunity to improve outcomes by treating MDD patients with SSRI/SNRI within 2 weeks and at or above the MTD within 4 weeks of diagnosis or less.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addi tion, cost of illness studies have documented stag ger ing direct and indirect eco nom ic costs as so ciated with MDD, of which more than half globally are attributable to TRD 20 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [20]
In the citing paper
“The relatively higher cost of illness attri buted to TRD is directly due to higher health care utilization and the need for higher inten sity treatments 20- 23 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [20]
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
No adjustments are needed for multiple comparisons.
Rothman, K. J. (1990) · Epidemiology · doi:10.1097/00001648-199001000-00010 · Cited by 5,965
Rosenbaum, P. R., & Rubin, D. B. (1985) · The American Statistician · doi:10.2307/2683903 · Cited by 4,774
Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference
Ho, D. E., Imai, K., King, G., & Stuart, E. A. (2007) · Political Analysis · doi:10.1093/pan/mpl013 · Cited by 4,205
Austin, P. C. (2011) · Pharmaceutical Statistics · doi:10.1002/pst.433 · Cited by 3,949
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 2,877
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Multivariate Statistical Modelling Based on Generalized Linear Models
Fahrmeir, L., & Tutz, G. (1994) · Springer Series in Statistics · doi:10.1007/978-1-4899-0010-4 · Cited by 1,391
Research works printed but not linked: 2
- WHO, 2008, The global burden of disease: 2004 update
- 10.1080/00031305.1985.10479383 · doi:10.1080/00031305.1985.10479383 · Paper page
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationThe Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder
Arnaud, A. M., Suthoff, E. D., Tavares, R. M., Zhang, X., & Ravindranath, A. J. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01021-w · Cited by 21
Clayton, A. H., Suthoff, E. D., Jain, R., Kosinski, M. R., Fridman, M., Deligiannidis, K. M., Meltzer-Brody, S. E., Chen, S., Gervitz, L. M., Huang, M., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.268 · Cited by 18
Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects
Mora, F., Ramos‐Quiroga, J. A., Baca‐García, E., Crespo, J. M., Gutiérrez-Rojas, L., Madrazo, A., Pérez-Costillas, L., Sáiz, P. A., Tordera, V., & Vieta, E. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1623659 · Cited by 11
Arnaud, A. M., Benner, J., Suthoff, E. D., WERNEBURG, B. G., Reinhart, M. L., Sussman, M., & Kessler, R. C. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.147 · Cited by 11
Metadata
- Authors
- McIntyre, R. S., Prieto, R., Schepman, P., Yeh, Y.-C., Boucher, M., Shelbaya, A., Chambers, R., Gao, X., & Pappadopulos, E.
- Affiliations
- University Health Network (CA)
- Saint Louis University (ES)
- Pfizer (United States) (US)
- Pharmerit (United States) (US)
- Pfizer (Canada) (CA)
- Corresponding author
- McIntyre, Roger S.
- ORCID
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2019-09-16
- Volume
- 35
- Issue
- 12
- Pages
- 2169-2177
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2965680320
- Cited by
- 15
- References
- 24
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 5 · 2021: 2
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- major depressive disorder, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, treatment initiation timing, healthcare resource utilization, health care costs, outpatient visits, antidepressant prescribing
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Adult, Antidepressive Agents, Cost-Benefit Analysis, Major Depressive Disorder, Depressive Disorder, Major, Female, Humans, Male, United States, Health Care Rationing, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Early Medical Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study. https://app.cochat.ai/papers/10.1080/03007995.2019.1652053
- The paper
- McIntyre, R. S., Prieto, R., Schepman, P., Yeh, Y.-C., Boucher, M., Shelbaya, A., Chambers, R., Gao, X., & Pappadopulos, E. (2019). Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2019.1652053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.